



FOR IMMEDIATE RELEASE

## **to-BBB Appoints Leonard Kruimer as Chief Financial Officer**

Leiden, the Netherlands, 9 January 2014 - [to-BBB](#), a biotechnology company that develops novel treatments for devastating brain disorders, today announced the appointment of Leonard Kruimer as Chief Financial Officer per January 1<sup>st</sup>, 2014. Mr. Kruimer brings to-BBB more than 30 years of experience in corporate finance, planning and strategy, including 15 years in senior executive positions in private and publicly listed biotechnology companies.

“I am delighted to have Leonard join our company,” commented Willem van Weperen, Chief Executive Officer of to-BBB. “We have been successful in attracting experienced industry executives with a deep understanding of the business. With the first two of our brain disease products in the clinic, we are now in an outstanding position to accelerate the company’s development.”

Leonard Kruimer was CFO and Management Board member of the Netherlands-based vaccine company Crucell from 1998 through to 2011, when Johnson & Johnson acquired the company. During his tenure at Crucell he was responsible for financing the company in private and public markets, including the IPO at Nasdaq and Euronext in 2000 and subsequent listing on the Swiss Stock Exchange in 2006. Mr. Kruimer was closely involved in the company’s M&A strategy, including the acquisition and integration of Swiss-based Berna Biotech. He served as the Chairman of the Supervisory Board of private biotech company ProFibrix from 2011 through to its acquisition by The Medicines Company (Nasdaq: MDCO) in 2013.

Prior to his time at Crucell, Leonard Kruimer was Managing Director at TIP Europe, a unit of GE Capital. Furthermore, he held senior executive positions at Kwik Fit and Continental Can, Inc. He was a consultant with McKinsey & Company and started his career at Price Waterhouse in New York. Mr. Kruimer holds an MBA from the Harvard Business School and is a Certified Public Accountant in New York State.

### **About to-BBB**

to-BBB is a clinical stage biotechnology company developing novel treatments for devastating brain disorders, such as brain cancer and neuroinflammatory diseases. The Company combines existing drugs with to-BBB’s proprietary G-Technology® to enhance drug delivery across the blood-brain barrier. to-BBB currently has two products in clinical trials: its lead product 2B3-101 is in a Phase IIa trial in Europe and the US for the treatment of primary brain tumors as well as brain metastases; the second product 2B3-201 for MS relapses and other neuroinflammatory diseases entered a Phase I clinical study in December 2013.

to-BBB is based in the Netherlands and its subsidiary to-BBB Taiwan Ltd. is based in Taipei, Taiwan. Investors in to-BBB include Aescap Venture, Antea Participaties, Jonghoud International and the Industrial Bank of Taiwan Management Corporation (IBTM).

**For more information:**

**Corporate Contacts:**

*Willem van Weperen, MSc, MBA*  
Chief Executive Officer

Phone: +31 71 33 222 51

E-mail: [WillemVanWeperen@toBBB.com](mailto:WillemVanWeperen@toBBB.com)

**to-BBB technologies BV**

J.H. Oortweg 19  
2333 CH Leiden  
The Netherlands  
[www.toBBB.com](http://www.toBBB.com)

*Sijme Zeilemaker, MSc*  
Business Development Manager

Phone: +31 71 33 222 56

E-mail: [SijmeZeilemaker@toBBB.com](mailto:SijmeZeilemaker@toBBB.com)

**to-BBB technologies BV**

J.H. Oortweg 19  
2333 CH Leiden  
The Netherlands  
[www.toBBB.com](http://www.toBBB.com)